Evecxia Therapeutics is a groundbreaking brand dedicated to harnessing the therapeutic potential of serotonin synthesis amplification for the treatment of mental illness. Founded by renowned neuropharmacologists Professor Marc Caron and Dr. Jacob Jacobsen from Duke University, Evecxia aims to enable individuals with mental disorders to lead more meaningful lives.

At the core of Evecxia's approach is the 5-hydroxytryptophan sustained-release (5-HTP SR) concept, which amplifies brain serotonin synthesis. Dr. Jacobsen's research has shown promising evidence of the clinical efficacy of 5-HTP, despite its limitations as a short-acting and poorly absorbed drug.

Evecxia focuses on prolonging 5-HTP's duration of action and improving its absorption to maximize its therapeutic benefits. The brand's dedicated and experienced leadership team, Board of Directors, Scientific Advisory Board, and consultants have unparalleled expertise in CNS drug development. They are committed to advancing Evecxia's drug candidates to the market to improve the lives of millions of patients with mental disorders.

Evecxia values serving patients above all else, ensuring capital efficiency, and embracing opportunities that align with their goal. By optimizing the value produced per dollar and maintaining a lean organization, Evecxia maximizes the impact of its funds towards drug development. With a strong focus on innovation, Evecxia Therapeutics is poised to make a significant impact in the field of mental health